SciELO - Scientific Electronic Library Online

 
vol.99 issue12Immunoexpression of p53 and cyclic D1 in adenomas of the gallbladder author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Revista Española de Enfermedades Digestivas

Print version ISSN 1130-0108

Abstract

BONNIN TOMAS, A.; VILA VIDAL, M.  and  ROSELL CAMPS, A.. Fecal calprotectin as a biomarker to distinguish between organic and functional gastrointestinal disease. Rev. esp. enferm. dig. [online]. 2007, vol.99, n.12, pp.689-693. ISSN 1130-0108.

Introduction: there is growing evidence showing the importance of the fecal calprotectin assay in differentiating organic from functional gastrointestinal disease. It is a simple, non-invasive biomarker that is especially useful in children, who may require general anesthesia for colonoscopy. The aim of this study was to assess the use and sensitivity of fecal calprotectin (FCP) in pediatric patients with signs and symptoms of IBD to avoid unnecessary invasive techniques and to distinguish between organic and functional gastrointestinal pathology. Material and methods: a single stool sample was collected from 47 children (mean age: 10.1 years) referred for non-specific gastrointestinal symptoms suggestive of organicity. On the basis of clinical criteria 13 children had functional bowel disorders and 34 had organic gastrointestinal disease, 15 with IBD and 19 with other organic (non-IBD) gastrointestinal conditions. Thirty healthy children were included as controls. Calprotectin concentrations were measured by enzyme immunoassay. Results: children with IBD had FCP levels [median (interquartile range); 1,219 μg/g (322-2,967 μg/g)] higher than children with functional gastrointestinal disease [20 μg/g (16-25 μg/g); p < 0.0001], those with organic non-IBD disease [113 μg/g (36-193 μg/g); p = 0.002], and healthy children [25 μg/g (19.2-32.5 μg/g); p < 0.0001]. Fecal calprotectin concentration also was significantly higher in children with organic (non-IBD) disease as compared to controls (p = 0.004) and children with functional pathology (p = 0.002). FCP levels were similar in controls and children with functional gastrointestinal disease (p = 0.264). Discussion: CPF is a sensitive, but not disease-specific, marker to identify patients with IBD who should undergo diagnostic colonoscopy, and to avoid unnecessary invasive procedures in patients with functional gastrointestinal disorders.

Keywords : Fecal calprotectin; Inflammatory bowel disease; Functional gastrointestinal diseases; Pediatry.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License